- Telehealth visits
- Insurance plan information
Anupama Kumar, MD
Hematology and Medical Oncology • Hematology and Medical Oncology (Multiple Myeloma)- Telehealth visits
- Insurance plan information
Anupama Kumar, MD
Hematology and Medical Oncology • Hematology and Medical Oncology (Multiple Myeloma)- Telehealth visits
- Insurance plan information
On this page
About me
Dr. Anupama Kumar is a hematologist-oncologist who specializes in caring for patients with multiple myeloma and other blood cancers. She also cares for patients who are undergoing treatments that include stem cell transplant, chemotherapy and cell therapies while in the hospital.
In research, Kumar leads clinical trials evaluating new treatments for patients with multiple myeloma.
Kumar earned her medical degree at Tufts University, where she also completed a residency in internal medicine. She completed a fellowship in hematology-oncology at University of California, San Diego, where she received specialized training in multiple myeloma and bone marrow transplant.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
- Hematology, American Board of Internal Medicine/Hematology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Hematology - Oncology, University of California Medical Center San Diego
Residency
- Internal Medicine, Tufts Medical Center
Internship
- Internal Medicine, Tufts Medical Center
Degree
- MD, Tufts University School of Medicine
Academic title
- Health Sciences Clinical Professor
My expertise
Specialties
- Hematology and Medical Oncology
- Hematology and Medical Oncology (Multiple Myeloma)
- Blood and Marrow Transplant and Cellular Therapy
Locations
My research
Clinical trials
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)Opens in a new window
Recruiting
The incidence and severity of AEs.Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaOpens in a new window
Recruiting
The number and percent of participants achieving BOR of partial response (PR) or better in quadruple class exposed participants received at least 4 prior lines...A Study to Evaluate Efficacy and Safety of Ciltacabtagene AutoleucelOpens in a new window
Recruiting
Participants in CR or better who achieve MRD-negative status at 12 months after cilta-cel infusion with a sensitivity of 10^-5, prior to progressive disease (P...
Publications
Showing 1-6 of 75 reviews
- July 24, 20265 out of 5 Stars
Dr. Anu Kumar is a very kind, knowledgeable and competent doctor. She asks pertinent questions and provides valid feedback for any issues or questions I might have.
- July 18, 20265 out of 5 Stars
The doctor was extremely good at answering my questions and explaining my treatment options.
- June 12, 20264 out of 5 Stars
Good
- May 3, 20265 out of 5 Stars
My health care team was very thorough in describing my proposed up-coming cell therapy.As well as explaining, with compassion, possible risks involved.
- April 17, 20265 out of 5 Stars
Very positive experience
- April 4, 20265 out of 5 Stars
Dr Kumar was patient and provided explanations for everything
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.